You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Bristol Myers
since
auto-detected in 7 stories
5 months ago
The company's future hinges on the success of Cobenfy, the company's new schizophrenia drug.
8 months ago
We're lowering our price target on Bristol Myers as two key overhangs persist ○
Shares were down around 5% on Thursday afternoon despite a beat-and-raise quarter.
9 months ago
Our bottom 5 stocks for the first half of 2025 — and why we still own them ○
This is what it will take to for a turnaround in shares of Salesforce, Apple, Bristol Myers, DuPont and Danaher.
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug ○
Cigna accused Bristol Myers Squibb of violating antitrust law by keeping generic versions of its blood cancer drug Pomalyst off the market to retain a monopoly.
10 months ago
Why the stock rally fizzled — plus, our latest thinking on Goldman and Bristol Myers ○
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
11 months ago
Why we're lowering our Bristol Myers price target despite an earnings beat, guidance raise ○
Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.
12 months ago
JPMorgan says own this drug stock. It's one Jim Cramer is itching to buy again ○
The Club remains optimistic about Bristol Myers and shares JPMorgan's enthusiasm about Cobenfy.
page 1 of 1